Latest Content

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

June 18th 2025, 3:00pm

By Spencer Feldman

Article

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

ctDNA-Guided Therapy May Improve Breast Cancer Outcomes

June 18th 2025, 1:00pm

By Dr. Julia E. McGuinness

Video

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

From Navigating the Unknown to Building a Movement: My DCIS Journey

June 17th 2025, 9:00pm

By Julia Stalder

Article

The bad news is you have ductal carcinoma in situ. The good news is that DCIS is the best type of breast cancer to get.

Zanzalintinib Triplet Combo Under Investigation in Kidney Cancer Subgroups

June 17th 2025, 8:00pm

By Dr. Michael Serzan

Video

Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma

How Insurance Red Tape Threatens Timely Cancer Care

June 17th 2025, 7:00pm

By Ryan Scott

Article

A study explores how prior authorization requirements; coverage stoppages and other red tape can generate barriers to life saving therapies in cancer care.

When Cancer and COVID Collide: The Diagnosis That Changed It All

June 17th 2025, 5:00pm

By Karen Cohn

Article

I was diagnosed with follicular lymphoma in 2020, during COVID, which forced me to retire early and taught me I’m more than a statistic.

Understanding the Importance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer

June 17th 2025, 4:00pm

By Ryan Scott

Article

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic breast cancer should know.

Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma

June 17th 2025, 3:00pm

By Spencer Feldman

Article

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.

New Treatment Options Emerging Across Lung Cancer Subtypes

June 17th 2025, 1:00pm

By Dr. Joshua K. Sabari

Video

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.

Cancer Recurrence, Getting Past the Anxiety

June 16th 2025, 9:00pm

By Sue McCarthy

Article

If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.

Understanding the Whole Person Behind their Cancer Diagnosis

June 16th 2025, 8:00pm

By Dr. Joshua K. Sabari

Video

Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.

Rybrevant Combo Improves Lung Cancer Outcomes After Tagrisso Failure

June 16th 2025, 7:00pm

By Ariana Pelosci

Article

Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.

How Scars and Journaling Helped Me Embrace Life After Colon Cancer

June 16th 2025, 5:00pm

By Carla Deschamps

Article

I became a colon cancer survivor after my 2020 diagnosis, and I share how my scars, mindset shifts and journaling helped me embrace this second chance.

Explaining Brain Cancer and Metastases Updates for Patients

June 16th 2025, 4:11pm

By Ryan Scott

Article

The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis

June 16th 2025, 3:00pm

By Spencer Feldman

Article

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.